Reduced Efficacy of Rosuvastatin by St. John's Wort

American Journal of Medicine

Volumn 122, Issue 2, 2009, Pages e1-

  Gordon, Ram Y ^a   Becker, David J ^a   Rader, Daniel J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSMARINUS OFFICINALIS EXTRACT; ROSUVASTATIN; SIMVASTATIN; SPIRULINA EXTRACT; UNCLASSIFIED DRUG;

ADULT; CASE REPORT; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERICUM PERFORATUM; INSOMNIA; LETTER; MALE; MEDICINAL PLANT; PRIORITY JOURNAL; ROSEMARY; SPIRULINA;

EID: 58649102491     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.09.033     Document Type: Letter

References (5)

1. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 136 (2002) 42-53
2. Markowitz J.S., Donovan J.L., DeVane C.L., et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290 (2003) 1500-1504
3. Andren L., Andreasson A., and Eggertsen R. Interaction between a commercially available St.John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol 63 (2007) 913-916
4. Eggertsen R., Andreasson A., and Andren L. Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand J Prim Health Care 25 (2007) 154-159
5. Xu H., Williams K.M., Liauw W.S., et al. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 153 (2008) 1579-1586